We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Researchers Identify RNAs Involved in Tumor Growth

By LabMedica International staff writers
Posted on 05 Sep 2017
Cancer researchers have linked a specific long non-coding RNA (lncRNA) to the growth and metastasis of certain types of cancer.

Long non-coding RNAs (lncRNAs) are considered to be non-protein coding transcripts longer than 200 nucleotides. More...
This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

Investigators at the Medical University of South Carolina (Charleston, SC, USA) were studying the contribution of lncRNAs to tumor progression and the regulatory mechanisms driving their expression.

They reported in the August 21, 2017, online edition of the journal Nature Cell Biology that they had characterized the binding of the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) to a nucleic acid structural element located in exon 12 of PNUTS (also known as PPP1R10) pre-RNA, which regulated its alternative splicing. HnRNP E1 release from this structural element, following its silencing, nucleocytoplasmic translocation, or in response to transforming growth factor beta (TGFbeta), allowed alternative splicing and generated a non-coding isoform of PNUTS.

Functionally the lncRNA called PNUTS was shown to serve as a competitive sponge for the microRNA miR-205 during epithelial–mesenchymal transition (EMT). In mesenchymal breast tumor cells and in breast tumor samples, the expression of lncRNA-PNUTS was elevated and correlated with levels of ZEB1 (Zinc finger E-box-binding homeobox 1) mRNAs. Simply put, breast and lung tumors grew faster and larger when their cells contained more PNUTS lncRNA.

Thus, PNUTS was determined to be a bifunctional RNA encoding both PNUTS mRNA and lncRNA-PNUTS, each eliciting distinct biological functions. While PNUTS mRNA was ubiquitously expressed, lncRNA-PNUTS appeared to be tightly regulated dependent on the status of hnRNP E1 and tumor context.

"My prediction is that this mechanism did not evolve to make just one long non-coding RNA," said senior author Dr. Philip H. Howe, professor of biochemistry and molecular biology at the Medical University of South Carolina. "There are probably others that are generated in this same fashion."

Related Links:
Medical University of South Carolina


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.